AbCellera Biologics (ABCL)
(Real Time Quote from BATS)
$3.81 USD
-0.09 (-2.31%)
Updated Apr 25, 2024 09:34 AM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for AbCellera Biologics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 38 | 485 | 375 | 233 | 12 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 38 | 485 | 375 | 233 | 12 |
Selling & Adminstrative & Depr. & Amort Expenses | 275 | 269 | 171 | 77 | 16 |
Income After Depreciation & Amortization | -237 | 217 | 204 | 156 | -4 |
Non-Operating Income | 63 | 27 | 20 | 8 | 2 |
Interest Expense | 0 | 4 | 5 | 7 | 0 |
Pretax Income | -174 | 239 | 219 | 158 | -2 |
Income Taxes | -28 | 81 | 66 | 39 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -146 | 159 | 153 | 119 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -146 | 159 | 153 | 119 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -206 | 250 | 222 | 162 | -2 |
Depreciation & Amortization (Cash Flow) | 31 | 33 | 17 | 6 | 2 |
Income After Depreciation & Amortization | -237 | 217 | 204 | 156 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 289.17 | 314.83 | 318.29 | 263.13 | NA |
Diluted EPS Before Non-Recurring Items | -0.51 | 0.50 | 0.48 | 0.45 | NA |
Diluted Net EPS (GAAP) | -0.51 | 0.50 | 0.48 | 0.45 | NA |
Fiscal Year end for AbCellera Biologics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 9.18 | 6.60 | 10.06 | 12.19 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 9.18 | 6.60 | 10.06 | 12.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 75.24 | 61.50 | 61.44 | 77.07 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -66.06 | -54.90 | -51.38 | -64.88 |
Non-Operating Income | NA | 17.45 | 15.61 | 13.39 | 16.73 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -48.60 | -39.28 | -38.00 | -48.15 |
Income Taxes | NA | -1.45 | -10.67 | -7.48 | -8.04 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -47.15 | -28.61 | -30.53 | -40.11 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -47.15 | -28.61 | -30.53 | -40.11 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 277.35 | 289.50 | 288.91 | 287.77 |
Diluted EPS Before Non-Recurring Items | NA | -0.17 | -0.10 | -0.11 | -0.14 |
Diluted Net EPS (GAAP) | NA | -0.16 | -0.10 | -0.11 | -0.14 |